The dıagnostıc Value of Serum autotaxın Level ın Colorectal Cancer
NCT ID: NCT06091592
Last Updated: 2023-10-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
129 participants
OBSERVATIONAL
2020-12-30
2021-12-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Immune Checkpoints in Predicting Response to Neoadjuvant Therapy in Rectal Cancer
NCT05457075
The Role of Serum Adipokines in Predicting Response to Neoadjuvant Therapy in Patients With Rectal Cancer
NCT04598984
Can Neoadjuvant Chemoradiotherapy be Ommited in Mid-rectal Cancer
NCT06823297
Study of Biomarkers in Tissue Samples From Patients With Metastatic Colon Cancer
NCT01012804
Significance of Cortactin Expression in Colorectal Adenocarcinomas
NCT05225870
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Autotaxin (ATX) molecule is a member of the nucleotide pyrophosphatase/phosphodiesterase enzyme family (ENNP), It is secreted at 125 kDa, has lysophospholipase D activity in the lysophosphatidic acid (LPA) pathway, and is located at the 24th locus of the long arm of the 8th chromosome. This is also called ENPP2. It was discovered to be an autocrine motility-stimulating factor released by human melanoma A-2058 cells . Lysophosphatidic acid (LPA) is a lipid signalling molecule located in the cell membrane. LPA functions as an autocrine/paracrine messenger through at least six G protein-coupled receptors (GPCR) known as LPA 1-6. It plays physiologically important roles in various cellular processes, including wound healing, differentiation, cell proliferation, and migration. The role of ATX in the bioactivity of LPA is correlated with the lysophosphatidyl-D (lysoPLD) activity of ATX. ATX molecule; With this enzyme activity, it plays a fundamental role in the conversion of lysophosphatidylcholine to lysophosphatidic acid . Many studies have demonstrated the biological effects of the autotaxin-lysophosphatidic acid (ATX-LPA) signalling pathway in cancer. In vitro and in vivo studies have shown that increased ATX-LPA signalling contributes to cancer initiation and progression. Current evidence supports the role of the ATX-LPA signalling pathway in the proliferation, invasion, adhesion, and angiogenesis of cells, and is effective in cancer development and metastasis. Increased ATX expression has been reported in various cancers, such as glioblastoma, hepatocellular and thyroid carcinomas, breast, pancreatic, colon, and hematological cancers .
The ATX molecule has the feature of being a molecule that will be effective in the future, not only in the diagnosis of cancer, but also in the treatment process and to be studied extensively. in this study, we aimed to examine the diagnostic and biological behaviour relationship between serum ATX levels and colorectal cancer and to determine the cut-off value for serum ATX levels in colorectal cancer.
Serum ATX levels were compared between the patient and control groups. ATX levels were analysed in subgroups formed according to the demographic, clinical, pathological, and laboratory characteristics of the patient group.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patient ( cancer)
. The colorectal cancer patient group included clinical stage 1-3 patients of both sexes. Patients with metastatic disease, those who received neoadjuvant therapy, those who received systemic chemoradiotherapy, those who had any known systemic inflammatory or autoimmune disease, those with another concurrent malignancy, and those who had been previously diagnosed and treated for another malignancy were excluded from the study.
Serum autotaxın levels
Autotaxin molecule is a nucleotide pyrophosphatase/phosphodiesterase enzyme.
Control (healthy volunteer)
The control group included healthy volunteers who had undergone screening colonoscopy within the last month, had no pathology, had not been diagnosed with any malignant disease before, had no known systemic inflammatory or autoimmune disease, and had not been diagnosed with inflammatory bowel disease.
Serum autotaxın levels
Autotaxin molecule is a nucleotide pyrophosphatase/phosphodiesterase enzyme.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Serum autotaxın levels
Autotaxin molecule is a nucleotide pyrophosphatase/phosphodiesterase enzyme.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* control group included healthy volunteers who had undergone screening colonoscopy within the last month , had no pathology,
Exclusion Criteria
* received neoadjuvant therapy
* received systemic chemoradiotherapy
* had any known systemic inflammatory or autoimmune disease
* had a with another concurrent malignancy
* had been previously diagnosed and treated for another malignancy
18 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Diskapi Yildirim Beyazit Education and Research Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
İsmail Oskay Kaya
PROFESSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ismail o kaya
Role: PRINCIPAL_INVESTIGATOR
Dışkapı Yıldırım Beyazıt training and research hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dışkapı Yıldırım Beyazıt training and research hospital
Ankara, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DYB-GC-AB-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.